These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 11016899)

  • 1. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
    Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
    Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone prevents fatty changes of the liver in obese diabetic rats.
    Jia DM; Tabaru A; Akiyama T; Abe S; Otsuki M
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1183-91. PubMed ID: 11106100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic abnormalities in the genetically obese and diabetic Otsuka Long-Evans Tokushima Fatty rat can be prevented and reversed by alpha-glucosidase inhibitor.
    Yamamoto M; Jia DM; Fukumitsu KI; Imoto I; Kihara Y; Hirohata Y; Otsuki M
    Metabolism; 1999 Mar; 48(3):347-54. PubMed ID: 10094112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats.
    Jia D; Taguchi M; Otsuki M
    Metabolism; 2005 May; 54(5):619-27. PubMed ID: 15877292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
    Jia D; Yamamoto M; Otani M; Otsuki M
    Metabolism; 2004 Apr; 53(4):405-13. PubMed ID: 15045684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
    Furuta M; Yano Y; Gabazza EC; Araki-Sasaki R; Tanaka T; Katsuki A; Hori Y; Nakatani K; Sumida Y; Adachi Y
    Diabetes Res Clin Pract; 2002 Jun; 56(3):159-71. PubMed ID: 11947963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP; Yu JG; Kruszynska YT; Olefsky JM
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats.
    Jia DM; Fukumitsu KI; Tabaru A; Akiyama T; Otsuki M
    Am J Physiol Regul Integr Comp Physiol; 2001 May; 280(5):R1332-40. PubMed ID: 11294751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troglitazone stimulates pancreatic growth in normal rats.
    Jia DM; Otsuki M
    Pancreas; 2002 Apr; 24(3):303-12. PubMed ID: 11893940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
    Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
    Kosegawa I; Chen S; Awata T; Negishi K; Katayama S
    Clin Exp Hypertens; 1999 Apr; 21(3):199-211. PubMed ID: 10225476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.
    Sreenan S; Sturis J; Pugh W; Burant CF; Polonsky KS
    Am J Physiol; 1996 Oct; 271(4 Pt 1):E742-7. PubMed ID: 8897863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
    Walli R; Michl GM; Mühlbayer D; Brinkmann L; Goebel FD
    Res Exp Med (Berl); 2000 Apr; 199(5):253-62. PubMed ID: 10815754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
    Willi SM; Kennedy A; Wallace P; Ganaway E; Rogers NL; Garvey WT
    Diabetes; 2002 Oct; 51(10):2895-902. PubMed ID: 12351424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of troglitazone on body fat distribution in type 2 diabetes.
    Akazawa S; Sun F; Ito M; Kawasaki E; Eguchi K
    Diabetes Care; 2000 Aug; 23(8):1067-71. PubMed ID: 10937499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats.
    Tagami S; Honda T; Yoshimura H; Homma H; Ohno K; Ide H; Sakaue S; Kawakami Y
    Tohoku J Exp Med; 2002 Jul; 197(3):169-81. PubMed ID: 12365558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.